Skip to content
Trident Lifeline logo

Trident Lifeline

543616 BSE
Price unavailable

Trident Lifeline (TLL) share price was ₹430.90 at the 28 Oct 2026 close; market capitalisation ₹516 Cr; P/E (TTM) 24.30; sector Healthcare. The share price rose 48.6% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 42.8% year on year to ₹33.72 Cr and net profit rose 82.4% year on year to ₹5.07 Cr (compared with Jun 2025). Promoters held 62.46% of Trident Lifeline in Sep 2026, down 0.13 percentage points from Jun 2026. Its Tapetide Score is 56/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹430.90 +140.85 +48.56% 1Y

Key Fundamentals

SMEPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹516 Cr
P/E (TTM)
24.3
EBITDA
₹38.60 Cr
Return on Equity
17.91%
Debt to Equity
0.73
Book Value
₹95.52
EPS (TTM)
₹17.73
52W High
₹437.90
52W Low
₹229.95

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,767.5035.064,24,082 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,655.0087.632,56,310 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,607.8072.341,75,266 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,186.70108.041,18,150 Cr22.290.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.8026.301,17,885 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.9034.681,11,755 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.1032.701,10,281 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Trident Lifeline (this company)
—24.30516 Cr4.510.12%17.91%21.81%164 Cr22 Cr
Median 8 companies₹1,767.5034.871,18,018 Cr4.790.47%14.56%18.45%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

56 Good
Overall score

Data confidence 98/100

Category scores

Quality Weak 45
Returns, margins, earnings quality 22% weight
Valuation Average 54
Cheap vs sector & own history 24% weight
Growth Strong 99
Sales & profit trajectory 9% weight
Financial Health Poor 33
Solvency, leverage, coverage 9% weight
Momentum Strong 91
Trend strength, vol-adjusted 12% weight
Ownership Average 51
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

3
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has high debtors of 209 days.
  • Promoter holding has decreased over last 3 years: -7.58%

Technical Indicators

Oscillators

Neutral

Bearish
3
Neutral
3
Bullish
3

Overall

Bullish

Bearish
3
Neutral
3
Bullish
13

Moving Averages

Bullish

Bearish
0
Neutral
0
Bullish
10

Growth Rate

Revenue Growth
46.53% lower than 3Y

change over 1 year

Net Income Growth
83.81% higher than 3Y

change over 1 year

Cash Flow Change
218%

change over 1 year

EBITDA Margin Change
13.93%

change over 1 year Operating margin 25.27% · Jun 2026

Quarterly Results

Particulars Mar 2023Jun 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
8.46
8.64
7.09
19.13
13.15
15.45
11.83
34.01
23.61
31.34
25.71
49.95
33.72
Expenses
6.52
6.88
5.66
16.77
10.66
11.4
7.76
25.47
18.44
24.48
20.62
38.96
25.2
Operating Profit
1.94
1.76
1.43
2.36
2.49
4.05
4.07
8.54
5.17
6.86
5.09
10.99
8.52
OPM %
22.93%
20.37%
20.17%
12.34%
18.94%
26.21%
34.4%
25.11%
21.9%
21.89%
19.8%
22%
25.27%
Other Income
0.64
0.33
0.25
1.47
1.15
0.54
0.56
1.87
1.35
1.67
4.63
1.62
0.57
Interest
0.15
0.1
0.15
0.37
0.49
0.5
0.55
1.55
1.13
0.99
1.24
0.77
0.86
Depreciation
0.12
0.13
0.19
0.39
0.54
0.16
0.61
2.74
1.46
0.91
2.46
1.23
1.62
PBT
2.31
1.86
1.34
3.07
2.61
3.93
3.47
6.12
3.93
6.63
6.02
10.61
6.61
Tax %
14.29%
24.73%
21.64%
46.91%
38.7%
28.5%
26.51%
-0.33%
29.26%
23.23%
22.76%
36%
23.3%
Net Profit
1.98
1.4
1.05
1.63
1.6
2.8
2.56
6.14
2.78
5.09
4.64
6.8
5.07
EPS (₹)
1.72
1.22
0.94
1.77
1.99
2.69
2.43
6.15
2.66
4.27
3.6
5.64
4.22
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
22
32
45
87
129
141
Expenses
19
25
36
72
101
109
Operating Profit
3
6
8
15
28
31
OPM %
12%
20%
18%
17%
22%
22%
Other Income
1
1
2
8
10
8
Interest
0
0
1
4
5
4
Depreciation
0
0
1
5
6
6
PBT
3
7
9
14
27
30
Tax %
-32%
8%
32%
23%
29%
—
Net Profit
4
6
6
10
19
22
EPS (₹)
4.94
5.24
5.51
10.22
15.96
17.73
Div. Payout %
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
8
12
12
12
12
Reserves
-3
34
41
53
88
Borrowings
2
8
18
54
73
Other Liabilities
7
9
16
37
62
Total Liabilities
14
63
87
156
236
Fixed Assets
1
3
21
44
61
CWIP
0
5
4
2
18
Investments
0
3
4
11
8
Other Assets
12
51
58
99
149
Total Assets
14
63
87
156
236
Figures in ₹ Crores

Cash Flow

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
-19
2
-4
5
Investing
0
-10
-20
-14
-37
Financing
1
42
11
14
34
Net Cash Flow
0
14
-7
-4
2
Free Cash Flow
-1
-26
-16
-15
-29
CFO/EBITDA
-8
-294
56
4
43
Figures in ₹ Crores

Ratios

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
83
139
110
116
209
Inventory Days
95
129
156
226
173
Days Payable
134
87
94
119
182
Cash Conversion Cycle
44
182
173
224
199
Working Capital Days
49
275
205
144
134
ROCE %
—
23%
15%
18%
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Trident Lifeline insights

62 extracted metrics + investor summaries across FY19–FY27.

Shareholding Pattern

DIIs0.21%Promot.62.46%FIIs1.16%Others11.44%Public24.73%As ofSep 2026
6.93% of promoter holding pledged as of 14 Oct 2026

Documents

Frequently Asked Questions about Trident Lifeline

What does Trident Lifeline Ltd do?
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals products[1]
Where is Trident Lifeline Ltd (TLL) listed?
Trident Lifeline Ltd trades under code 543616 on the BSE.
Which sector does Trident Lifeline Ltd belong to?
Trident Lifeline Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Trident Lifeline Ltd?
Trident Lifeline Ltd has a market capitalisation of ₹516.26 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Trident Lifeline Ltd?
Trident Lifeline Ltd trades at a PE ratio of 24.30 as of 28 Oct 2026, on earnings per share of ₹17.73, against a book value of ₹95.52 per share.
What is the 52-week high and low of Trident Lifeline Ltd?
Over the last 52 weeks Trident Lifeline Ltd has traded between ₹229.95 and ₹437.9 as of 28 Oct 2026.
Does Trident Lifeline Ltd pay dividends?
Trident Lifeline Ltd has a dividend yield of 0.12%.
What is the Return on Equity (ROE) of Trident Lifeline Ltd?
Trident Lifeline Ltd reported a return on equity of 17.91%. Its debt-to-equity ratio is 0.73.

Company Information

Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals products[1]

Website tridentlifeline.com
Listed 2022-10-10
Face Value ₹ 10
Shares Outstanding 1,19,80,925

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/543616.md for Trident Lifeline Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month